PFIZER INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)
Phase 3
Completed
- Conditions
- Macular Degeneration
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2007-05-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 90
- Registration Number
- NCT00150202
- Locations
- π―π΅
Pfizer Investigational Site, Kyoto, Japan
To Evaluate the Safety and Efficacy of Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy.
Phase 3
Completed
- Conditions
- Diabetic Neuropathy, Painful
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2007-01-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 384
- Registration Number
- NCT00150423
Evaluation of Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.
Phase 3
Completed
- Conditions
- Seizure Disorder, Partial
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 337
- Registration Number
- NCT00150293
- Locations
Pfizer Investigational Site
Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer
Phase 1
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2013-10-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 282
- Registration Number
- NCT00147537
- Locations
- πͺπΈ
Pfizer Investigational Site, Sevilla, Spain
Compare Effectiveness of Eplerenone vs Atenolol in Reversing the Remodelling Resistance Arteries in Subjects With HT
Phase 4
Completed
- Conditions
- Hypertension
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2008-04-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 34
- Registration Number
- NCT00147563
- Locations
- π¨π¦
Pfizer Investigational Site, Montreal, Quebec, Canada
Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2013-01-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 264
- Registration Number
- NCT00147498
- Locations
- πͺπΈ
Pfizer Investigational Site, Sevilla, Spain
Study To Examine Effect Of CP-866,087 On Consumption And Craving Of Alcohol In Alcohol Dependent Subjects.
Phase 2
Completed
- Conditions
- Alcoholism
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2012-10-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 88
- Registration Number
- NCT00147576
- Locations
- πΊπΈ
Pfizer Investigational Site, San Antonio, Texas, United States
A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2008-08-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 37
- Registration Number
- NCT00147485
- Locations
- πΊπΈ
Pfizer Investigational Site, Philadelphia, Pennsylvania, United States
Non-Comparative Study To Evaluate Changes In FMD After Quinapril Therapy In Hypertensive Women
Phase 4
Completed
- Conditions
- MenopauseHypertension
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2007-04-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 70
- Registration Number
- NCT00147524
- Locations
- ππΊ
Pfizer Investigational Site, Szombathely, Hungary
MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2013-09-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 79
- Registration Number
- NCT00147550
- Locations
- πΊπΈ
Pfizer Investigational Site, Cleveland, Ohio, United States
Β© Copyright 2025. All Rights Reserved by MedPath